Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human (FIH), multicenter, open-label, uncontrolled, Phase 1/2a study with
dose escalation in patients with advanced solid tumors (Part 1) and cohorts of up to 15
patients per selected indication (Part 2). The solid tumor types in Part 2 will be decided by
the sponsor prior to the start of Part 2, but not be solely based on the efficacy results in
Part 1.